Last Updated on November 4, 2024 by The Health Master
Thiamine
In a significant development for the Indian pharmaceutical industry, the Department of Pharmaceuticals (DoP) Govt of India (Govt) has overturned a decision by the National Pharmaceutical Pricing Authority (NPPA) regarding the ceiling price of a thiamine injection.
The DoP has referred the matter back to the NPPA for recalculation after identifying errors in the previous calculation.
The Dispute
The dispute arose when Ordain Health Care Global, a pharmaceutical company based in Tamil Nadu, challenged the ceiling price set by the NPPA for its thiamine 100 mg injection.
The company argued that the NPPA had incorrectly considered a fixed dose combination drug from another company in its calculations.
Additionally, Ordain Health Care Global contended that the NPPA had failed to account for a recent increase in the Wholesale Price Index (WPI), which should have resulted in a higher ceiling price.
NPPA’s Response
The NPPA defended its decision, stating that Ordain Health Care Global had not submitted the required forms within the prescribed time limits.
The authority also argued that the company had not raised any objections to the draft ceiling price within the specified timeframe.
However, the NPPA did agree that one of the brands considered in its calculations, Vitneurin AQ 100 mg injection 2 ml, should be excluded as it is a fixed dose combination drug.
DoP’s Intervention
After reviewing the case, the DoP found merit in Ordain Health Care Global’s arguments.
The department concluded that the NPPA had indeed erred in its calculations and that the ceiling price for the thiamine injection should be recalculated.
Senior economic advisor Awadhesh Kumar Choudhary noted that the company’s failure to raise objections within the prescribed time should not deprive it of its legitimate pricing rights.
Implications for the Pharmaceutical Industry
The DoP’s decision is a significant victory for Ordain Health Care Global and could have broader implications for the Indian pharmaceutical industry.
It highlights the importance of accurate pricing calculations and the need for timely responses from regulatory authorities.
The case also underscores the potential for companies to challenge pricing decisions if they believe they are unfair or unjustified.
Disclaimer: This article contains information derived from the source mentioned below. Our team utilized an AI language model to rewrite and present the news or article in a unique format.
NPPA revised Ceiling price of 11 scheduled formulations: October 2024
NPPA fixed retail price of 20 formulations: October 2024
NPPA revises ceiling prices of these 8 Essential Drugs
NPPA fixed retail price of 62 formulations: September 2024
NPPA revised Ceiling price of 4 scheduled formulation: August 2024
NPPA revised Ceiling price of 1 scheduled formulation: May 2024
DTAB recommends changes to New Drugs and Clinical Trials Rules
NPPA revised Ceiling price of 11 scheduled formulations: October 2024
New Drugs, Medical Devices and Global Standards: India’s Regulatory Advancements
NPPA fixed retail price of 20 formulations: October 2024
19th ICDRA – Day 2nd: Key Highlights from the Workshop
Drug recall: Glenmark recalls drugs for manufacturing issues
Drug Regulatory System of India gains Global Recognition
NPPA revises ceiling prices of these 8 Essential Drugs
DTAB’s recommendations about tackling the Antimicrobial Resistance Crisis
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
